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Contrast echocardiography, tumors and thrombus:
A new episode in a 50-year history
L’échocardiographie de contraste : un nouvel épisode dans une histoire
longue de 50 ans
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Received 20 February 2009; accepted 20 February 2009Contrast echocardiography has been associated with the development of echocardiog-
raphy for almost 50 years. During the 1960s, early work on M-mode echocardiography
involved contrast, in order to identify intraventricular structures and the endocardium
[1]: injections of indocyanine green brought microbubble opaciﬁcation of the left ven-
tricle. During the 1970s, the principles supporting the detection of right-to-left shunts
with the use of agitated saline were established [2]. During the early 1980s, attempts
were made to compare velocity derived from M-mode contrast traces and Doppler [3].
Towards the end of this decade, long-term research ﬁnally resulted in multicentre tri-
als dedicated to transpulmonary contrast agents [4]. Three years later, the contribution
of this technology to a better delineation of the endocardium was documented [5]. At
that time, harmonic imaging was patented initially for studying contrast; its remark-
able capabilities without contrast gave the impression that it could cover most clinical
needs. The value of a combination of contrast and harmonic imaging was ﬁnally clearly
established, in particular by Laﬁtte et al. [6]. The next major step was the assess-
ment of myocardial perfusion by contrast as proposed at the end of the 1990s [7].
This approach has been supported by new signal processing, allowing sensitive detec-
tion with low mechanical index and low bubble destruction. During the past 10 years,
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[64
e have seen a succession of good and bad news regarding
he registration and reimbursement of transpulmonary con-
rast agents. A few post-marketing side-effects have created
oncerns and led to the modiﬁcation of recommendations,
ut analyses from databases have, again, documented the
atisfactory safety proﬁle of contrast echocardiography [8].
evertheless, the indication for perfusion analysis has not
et been approved.
In this less than enthusiastic context, the work reported
y Mansencal et al. [9] offers positive and useful data that
ay have an impact on clinical practice. The report is based
n a series of heart tumours and thrombi that were imaged
y contrast echocardiography in conditions that were in
greement with the present recommendations: left cavity
paciﬁcation for better delineation of structures. Indeed,
urrent settings with low mechanical index provide simulta-
eously the best imaging of the cavity and some information
n perfusion. The authors suggest adding to the analysis of
he cavity a careful reading of the contrast enhancement of
ass (absent, partial or total). Their results show good dif-
erentiation between thrombus and metastasis in patients
ith a known extracardiac primary tumour, as well as an
mproved wall motion analysis (and, thus, diagnosis accu-
acy), in post-infarct patients. These new data conﬁrm their
revious work on thrombus [10]. With regard to the differ-
ntial diagnosis between tumour and thrombus, these data
gree with an older but smaller series that relied on a type of
uantiﬁcation instead of visual reading [11]. More recently
eported cases further reinforce the message [12,13].
For the future, two additional dimensions may provide
dditional beneﬁts. On the one hand, the work has been
onducted in masses seen on the initial echocardiogram
nd does not address the question of the sensitivity of this
omographic method: could this sensitivity be improved by
combination of three-dimensional echocardiography with
ontrast? On the other hand, since computed tomography
nd magnetic resonance imaging are becoming more widely
vailable, the question of a multimodality approach might
e discussed, potentially leaving the door open for a multi-
entre registry study.eferences
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